Evgen Pharma PLC (AIM:EVG) has confirmed its development partner Stalicla SA has pooled together US$17.4 million from a Series B fundraise to help it with the development of the STP1 asset.
Dr Huw Jones, Evgen CEO, said: "We extend our congratulations to Stalicla on this round of financing and look forward to continuing discussions on SFX-01 in ASD."